Trial Profile
Study of CUDC 305 to assess the safety and efficacy in patient with systemic mastocytosis and glioblastoma multiforme.
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 12 May 2015
Price :
$35
*
At a glance
- Drugs RGRN-305 (Primary)
- Indications Glioblastoma; Systemic mastocytosis
- Focus Therapeutic Use
- 12 May 2015 New trial record